A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Relatlimab
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Cisplatin

Sponsor

Bristol-Myers Squibb